We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

79 hedge funds and large institutions have $161M invested in Ovid Therapeutics in 2020 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 18 increasing their positions, 17 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

240% more capital invested

Capital invested by funds: $47.3M → $161M (+$114M)

129% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 17

77% more call options, than puts

Call options by funds: $768K | Put options by funds: $434K

39% more funds holding

Funds holding: 57 → 79 (+22)

10.89% more ownership

Funds ownership: 29.02% → 39.91% (+11%)

6% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 17

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
79
Holders Change
+22
Holders Change %
+38.6%
% of All Funds
1.62%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
39
Increased
18
Reduced
17
Closed
17
Calls
$768K
Puts
$434K
Net Calls
+$334K
Net Calls Change
+$334K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$11.3M
2
BI
BVF Inc
California
+$5.17M
3
State Street
State Street
Massachusetts
+$3.44M
4
Invesco
Invesco
Georgia
+$3.16M
5
Northern Trust
Northern Trust
Illinois
+$2.04M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.42M
2
CA
CHI Advisors
New York
-$1.33M
3
IC
Ikarian Capital
Texas
-$1.13M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.1M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$21.5M +$11.3M +2,424,104 +495%
CCM
2
Consonance Capital Management
New York
$18.9M -$46.8K -10,000 -0.4%
BI
3
BVF Inc
California
$17.6M +$5.17M +1,106,147 +86%
Vanguard Group
4
Vanguard Group
Pennsylvania
$15.6M +$1.98M +422,661 +25%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$13.1M -$1.42M -303,685 -15%
State Street
6
State Street
Massachusetts
$5.42M +$3.44M +735,956 New
Axa
7
Axa
France
$5.23M -$496K -106,122 -13%
Invesco
8
Invesco
Georgia
$4.98M +$3.16M +675,900 New
Renaissance Technologies
9
Renaissance Technologies
New York
$4.6M -$1.07M -228,734 -27%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$4.33M +$1.37M +293,721 +100%
CA
11
CHI Advisors
New York
$4.01M -$1.33M -284,132 -34%
Millennium Management
12
Millennium Management
New York
$3.85M +$578K +123,638 +31%
Wells Fargo
13
Wells Fargo
California
$3.84M +$143K +30,614 +6%
Assenagon Asset Management
14
Assenagon Asset Management
Luxembourg
$3.76M +$1.83M +390,242 +325%
Northern Trust
15
Northern Trust
Illinois
$3.73M +$2.04M +435,638 +624%
BBA
16
Baker Bros. Advisors
New York
$3.38M +$1.82M +388,782 +560%
TCM
17
Tekla Capital Management
Massachusetts
$2.75M – – –
PIM
18
Platinum Investment Management
Australia
$2.22M -$380K -81,346 -21%
RCM
19
RA Capital Management
Massachusetts
$2.1M +$1.33M +285,000 New
N
20
Nuveen
North Carolina
$1.5M +$951K +203,275 New
Connor, Clark & Lunn Investment Management (CC&L)
21
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.4M +$147K +31,380 +20%
EI
22
EAM Investors
California
$1.36M – – –
Morgan Stanley
23
Morgan Stanley
New York
$1.11M +$135K +28,826 +24%
UBS Group
24
UBS Group
Switzerland
$980K -$351K -74,974 -36%
FC
25
Fairpointe Capital
Illinois
$934K -$70.2K -15,000 -11%
1
2 3 4

OVID Hedge Fund Activity: Q2 2020 in Review

79 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q2 2020, worth a combined $161M — up 240% from $47.3M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new OVID positions and 17 closed out — a net gain of 22 holders — while 18 added to existing stakes and 17 trimmed.

The largest buyer was BlackRock, adding an estimated $11.3M. The largest seller was Fidelity Investments, cutting an estimated $1.42M.

  • 79 institutional investors held Ovid Therapeutics (OVID) as of Q2 2020, up from 57 in Q1 2020.
  • Funds reported $161M of Ovid Therapeutics stock for Q2 2020, up 240% quarter-over-quarter.
  • 39 funds opened new Ovid Therapeutics positions in Q2 2020 and 17 closed out, a net change of +22 holders.
  • The largest Ovid Therapeutics buyer in Q2 2020 was BlackRock, an estimated $11.3M added.
  • The largest Ovid Therapeutics seller in Q2 2020 was Fidelity Investments, an estimated $1.42M sold.

Based on aggregated 13F filings for Q2 2020.